Patents by Inventor Peter ULRICHTS
Peter ULRICHTS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240325528Abstract: Provided herein are unit dosage forms of a biologic that are determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.Type: ApplicationFiled: February 2, 2024Publication date: October 3, 2024Inventors: Antoinetta Jacoba Maria VAN BRAGT, Peter Ulrichts, Erik Hofman, Peter Verheesen
-
Publication number: 20230265201Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: ApplicationFiled: July 11, 2022Publication date: August 24, 2023Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
-
Patent number: 11505585Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: GrantFiled: November 22, 2017Date of Patent: November 22, 2022Assignees: argenx BV, The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 11434298Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: GrantFiled: February 18, 2019Date of Patent: September 6, 2022Assignee: ARGENX BVInventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
-
Publication number: 20220275035Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: February 15, 2022Publication date: September 1, 2022Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 11072665Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.Type: GrantFiled: February 19, 2015Date of Patent: July 27, 2021Assignee: argenx BVBAInventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
-
Publication number: 20200024344Abstract: A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists.Type: ApplicationFiled: June 7, 2019Publication date: January 23, 2020Inventors: Hans de Haard, Peter Ulrichts, Thierry Cousin, Nicolas Leupin, Torsten Dreier, Tonke Van Bragt
-
Publication number: 20190270823Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: ApplicationFiled: February 18, 2019Publication date: September 5, 2019Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
-
Publication number: 20190194277Abstract: Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.Type: ApplicationFiled: December 7, 2018Publication date: June 27, 2019Inventors: Johannes de Haard, Torsten Dreier, Peter Ulrichts, Antonio Guglietta, Nicolas Leupin
-
Patent number: 10316073Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: GrantFiled: December 23, 2014Date of Patent: June 11, 2019Assignees: argenx BVBA, The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20180179258Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: November 22, 2017Publication date: June 28, 2018Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 9926364Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.Type: GrantFiled: November 5, 2012Date of Patent: March 27, 2018Assignee: ARGEN-X N.V.Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier
-
Publication number: 20170369581Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: ApplicationFiled: February 19, 2015Publication date: December 28, 2017Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
-
Patent number: 9765148Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.Type: GrantFiled: March 16, 2012Date of Patent: September 19, 2017Assignee: ARGEN-X N.V.Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
-
Patent number: 9765149Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: GrantFiled: January 24, 2014Date of Patent: September 19, 2017Assignee: ARGEN-X N.V.Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
-
Publication number: 20160264669Abstract: Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).Type: ApplicationFiled: March 8, 2016Publication date: September 15, 2016Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, Nicolas G.H. Ongenae
-
Publication number: 20160207996Abstract: The present invention relates to antibodies and antigen binding fragments thereof derived from antibodies raised by DNA immunization of host animals, particularly camelids (e.g. llama). The antibodies and antigen binding fragments thereof bind to proteins which may be particularly large in size (at least 1115 amino acids in length), or have at least 8 transmembrane domains, or are naturally encoded by nucleotide sequences which are difficult to replicate in standard or common E. coli strains. The present invention also relates to antibodies and antigen binding fragments thereof which bind to ion channels, in particular the voltage-gated sodium channel Nav1.7. Methods of raising antibodies against particular protein targets by a process of DNA immunization are also provided.Type: ApplicationFiled: September 5, 2014Publication date: July 21, 2016Inventors: Peter Ulrichts, Sebastian Van Der Woning, Gitte De Boeck, Erik Hofman, Christophe Blanchetot, Michael Saunders, Johannes Joseph Wilhelmus De Haard
-
Publication number: 20150266963Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: ApplicationFiled: February 19, 2015Publication date: September 24, 2015Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
-
Publication number: 20150218239Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: December 23, 2014Publication date: August 6, 2015Applicants: arGEN-X B.V., The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20140286976Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.Type: ApplicationFiled: November 5, 2012Publication date: September 25, 2014Applicant: arGEN-X B.V.Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier